Bethyl Laboratories, Inc., a leading supplier of antibody products and custom antibody services, has won the 2021 CiteAb Researchers’ Choice Award. The CiteAb awards recognize both suppliers and individuals who make notable contributions in the life sciences reagent sector.
Fortis Life Sciences, a life sciences company offering products and solutions for the life sciences industry, has acquired the premium antibody company Bethyl Laboratories. Based in Montgomery, Texas, Bethyl Laboratories has a long history of offering the highest quality primary and secondary antibodies to its customers, as well as other protein detection reagents. Bethyl Laboratories is well known for industry leading performance and the highest standards in antibody validation, and prior to the acquisition by Fortis, had successfully operated as a private, family-owned, and operated business for nearly 50 years.
Biocare Medical and Bethyl Laboratories Announces the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications
August, 4 2020 – Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.
SAN FRANCISCO and MONTGOMERY, Texas, June 29, 2020 — Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces a collaborative partnership with Bethyl Laboratories to develop targeted antibodies for cancer research and oncology diagnostics.
Fluidigm Press Release: New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration with Bethyl Laboratories to provide broader verified antibody access for researchers using Fluidigm’s Imaging Mass Cytometry™ (IMC™) technology.